Thyroid Function Affects the Risk of Post-stroke Depression in Patients With Acute Lacunar Stroke

Jianglong Guo 1, Jinjing Wang 2, Yue Xia 1, Shiyi Jiang 1, Pengfei Xu 1, Chunrong Tao 1, Wen Sun 1* and Xinfeng Liu 1*

1 Stroke Center and Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, 2 Department of Neurology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China

Objective: This study aimed to investigate whether thyroid function profiles are associated with post-stroke depression (PSD) and evaluate the mediation effect of cerebral small vessel disease (cSVD) on the association of thyroid function profiles and PSD in patients with acute ischemic lacunar stroke.

Methods: In this study, 372 patients with confirmed acute ischemic lacunar stroke within 3 days of onset were consecutively recruited. Serum levels of thyroid hormones and thyroid antibodies were detected on admission. Lacunar infarcts, white matter lesions, cerebral microbleeds, and enlarged perivascular spaces were rated using validated scales. The severity of depression was scored with the 24-item Hamilton Depression Scale in the hospital after a week of stroke onset. Multivariate regression was utilized to analyze the association of thyroid function profiles and PSD. Mediation analysis was employed to evaluate the effect of cSVD on the association of thyroid function profiles and PSD.

Results: A total of 87 (23.4%) participants were diagnosed with depression after stroke. Serum thyroid-stimulating hormone (TSH) levels were significantly higher in patients with PSD than in those without PSD, while free triiodothyronine (FT3) and free thyroxine (FT4) were not significantly different between the two groups. After adjusting for potential confounders, serum TSH levels were positively associated with the risk of PSD (OR = 1.228; 95% CI: 1.053–1.431, p = 0.009). A similar association was also found between the total cSVD burden score and PSD (OR = 2.137; 95% CI: 1.634–2.793, p < 0.001). Further mediation analysis indicated that 26.37% of the association between TSH and PSD was mediated by cSVD.

Conclusions: Serum TSH levels on admission can probably predict depression after acute ischemic lacunar stroke.

Keywords: thyroid dysfunction, TSH, post-stroke depression, cerebral small vessel disease, stroke
INTRODUCTION

Stroke is the second leading cause of death and the third leading cause of disability worldwide (1–3). Most survivors are vulnerable to neuropsychological complications, including depression (4), anxiety (5), fatigue (6, 7), dementia (8), apathy (9), and insomnia (10). Post-stroke depression (PSD) is the most common subtype and commonly refers to a depressive state after stroke onset (11). The frequency of PSD has been investigated in many studies worldwide. Different studies always concluded different results. Approximately one-third of patients who had stroke are affected by PSD (12). The existence of PSD not only brings a heavy financial burden to individuals but also hinders the process of stroke rehabilitation.

Thyroid hormones are essential for brain development and are also important factors to warrant brain functions throughout life (13). It has been shown that during the reorganization of the brain after a stroke, brain development mechanisms may be reactivated and involve cascades regulated by thyroid hormones (14). Moreover, a considerable number of studies have indicated that thyroid dysfunction is associated with the risk of stroke (15) as well as adverse stroke outcomes (13, 16). Additionally, the relationship between thyroid function and depression has long been recognized (17). Patients with thyroid disease are more likely to have depression symptoms. In contrast, depression may be accompanied by various subtle thyroid abnormalities. Thus, we speculate that thyroid dysfunction is also associated with PSD.

With the development of medical imaging technology, cerebral small vessel disease (cSVD) has been widely studied. cSVD is used to describe a group of pathological processes that affect small vessels of the brain (18). On the one hand, an increasing number of evidence links cSVD to PSD (19, 20). Zhang et al. conducted a magnetic resonance imaging-based cohort study and demonstrated that the total magnetic resonance imaging burden of cSVD is associated with PSD in patients who had stroke (19). Another study including 294 patients revealed that cSVD is associated with late-onset depression and increases the risk for PSD (20). On the other hand, investigators demonstrated that cSVD was also associated with thyroid dysfunction (21). All these results raise the question of whether cSVD can be regarded as a mediating factor in the relationship between thyroid dysfunction and PSD.

Therefore, our purpose was to investigate the association between thyroid dysfunction and PSD and to evaluate the effect of cSVD on the association in patients with acute ischemic lacunar stroke.

METHODS

Participants

Patients with first-ever acute ischemic lacunar stroke hospitalized at the First Affiliated Hospital of USTC were included from September 2019 to July 2021. Lacunar stroke was defined as an acute stroke syndrome with a round or ovoid, subcortical, small deep infarct (diameter < 15 mm) based on diffusion-weighted imaging (DWI). If there were no visible lesions on baseline MRI, we employed pre-defined clinical criteria for specific clinical lacunar syndromes (22). Each patient was subjected to a series of examinations, including neurological investigations, blood tests, and MRI scans. We used the National Institutes of Health Stroke Scale (NIHSS) to assess the stroke severity of patients on admission. The inclusion criteria were as follows: (1) patients older than 18 years; (2) first-ever acute lacunar stroke; (3) within 3 days of stroke onset. Patients with (1) pre-existing thyroid diseases (such as thyroid inflammation, Goiter, Thyroid tumors, etc.); (2) communication barriers; (3) presence of cancer or other chronic diseases that easily cause mood disorders; (4) a cardioembolic source of stroke; (5) over 50% stenosis of the affected large artery; (6) other stroke types and unexplained strokes type were excluded. We also excluded those with a history of depression or on any medication that could affect emotional status or thyroid functions (such as antidepressants, estrogen, androgen, and glucocorticoids) (23). Written informed consent was obtained from all participants. The study protocol was approved by the local Ethical Committee on Human Experimentation, and our clinical registration number was ChiCTR2100043886.

Measurements of Thyroid Hormones

Blood samples for thyroid function tests were collected within 24 h after admission. The serum was separated from blood and then stored at −80°C. Standardized radioimmunoassay kits (Beckman Coulter, USA) were employed to measure serum levels of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4). Additionally, anti-thyroglobulin antibodies (TGAb) and thyroid microsomal antibody (TMAb) were also detected.

Measurements of Depression

Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria were used for the diagnosis of depression for all patients, and the severity of depression was scored by the 24-item Hamilton Depression Scale (HAMD-24) (24) in the hospital after a week of stroke onset. Two clinicians made the diagnosis of depression according to DSM-V, and they did not know the thyroid hormone information of all patients who had stroke. The HAMD-24 has been widely used by investigators due to its proven reliability and validity among patients who had stroke (25, 26). It includes 24 items, and each item is scored from 0 to 2 or 0 to 4. Finally, the scores for each item were summed to obtain the total score. The highest total score indicates the most severe depression. In addition, the Chinese version of the Lubben Social Network Scale (27) was also employed in evaluating interpersonal communication.

Neuroimaging Assessment

All patients underwent a 3-T brain MRI scan (Signa HD, General Electric Company, Fairfield, CT, USA) within 7 days after admission. Sequences included T1-weighted, T2-weighted, DWI, fluid-attenuated inversion recovery (FLAIR), and axial susceptibility-weighted imaging (SWI).
There are four main kinds of imaging markers of cSVD: white matter hyperintensities (WMH), lacunar infarcts (Lis), cerebral microbleeds (CMBs), and enlarged perivascular spaces (EPVSs) (28–31). In brief, CMBs were defined as small (diameter < 10 mm) homogenous rounded lesions of signal loss on SWI (32). Both periventricular WMH and deep WMH were graded using the Fazekas scale from 0 to 3 on FLAIR images (33). Extensive WMHs referred to deep white matter ≥ 2 score or periventricular white matter with 3 score. Enlarged perivascular space (EPVS) was identified as round, oval, or linear-shaped lesions with signal intensity equal to the cerebrospinal fluid and without a T2-hyperintense rim on FLAIR imaging (34). They were hyperintensities on T2-weighted images and were rated in the basal ganglia or centrum semiovale. We used a three-category ordinal scale to assess the severity of EPVS in the basal ganglia or centrum semiovale (mild, 0–10; moderate, 11–25; extensive, > 25).

According to neuroimaging standards for cSVD (34), the total burden of cSVD ranging from 0 to 4 was calculated by accumulating four markers of cSVD. Each marker of cSVD was awarded 1 point based on the following principle: (1) presence of Lis, (2) presence of CMBs, (3) extensive WMLs, and (4) moderate to extensive EPVS (30).

#### Statistical Analyses

Normal distribution of the study data was detected by the Kolmogorov–Smirnov test. Continuous variables are expressed as the means (SD) or median (IQR) as appropriate. Categorical variables are expressed as numbers (percentages). The differences between the PSD group and the non-PSD group were compared using Student’s t-test or Mann–Whitney’s U-test for continuous variables and χ²-test or Fisher exact test for categorical variables. Logistic regression was employed to assess the association between thyroid hormone levels and PSD. In addition, we performed mediation analysis to examine the mediating effect of cSVD on the association between serum TSH level and the risk of PSD. Serum TSH level was a predictor variable (X); total burden of cSVD was a mediator (M); PSD was an outcome variable (Y). The bootstrap method was used to test the mediation effect. A p-value of 0.05 was considered statistically significant. All data were analyzed with SPSS software (SPSS for Windows, version 23).

### RESULTS

#### Baseline Characteristics of Study Participants

As presented in Figure 1, we finally enrolled a total of 372 participants in the present study, 87 (23.4%) of whom were diagnosed with PSD. The mean age of the participants was 58.6 ± 12 years. The demographic data and thyroid function profiles are shown in Table 1. No significant difference was found in sex, hypertension, diabetes mellitus (DM), smoking, body mass index (BMI), serum glucose (GLU), hemoglobin (HB), or total cholesterol (TC) between the PSD group and the non-PSD group. However, the two groups showed significant differences in terms of age (p = 0.043), NIHSS score (p = 0.002), C-reactive protein (CRP) (p = 0.002), uric acid (UA) (p = 0.006), T3 (p = 0.043), TSH (p = 0.027), and Lubben score (p = 0.002).
TABLE 1 | Baseline characteristics of study participants without and with PSD.

| Characteristics | All study patients (n = 372) | Non-PSD (n = 285) | PSD (n = 87) | p-value |
|-----------------|-------------------------------|-------------------|-------------|---------|
| Age, mean (SD), y | 58.6 (12.0) | 57.9 (12.7) | 60.9 (9.2) | 0.043* |
| Female n (%) | 117 (31.5) | 84 (29.5) | 33 (37.9) | 0.137 |
| Hypertension, n (%) | 246 (66.1) | 177 (62.1) | 69 (78.3) | 0.245 |
| DM n (%) | 114 (30.6) | 81 (28.4) | 33 (37.9) | 0.092 |
| Smoking, n (%) | 135 (36.3) | 105 (36.8) | 30 (34.5) | 0.689 |
| NIHSS score, median (IQR) | 2.0 (1.0–4.0) | 2.0 (0–4.0) | 2.0 (2.0–4.0) | 0.002* |
| BMI, mean (SD), kg/m² | 25.0 (3.3) | 24.8 (3.2) | 25.6 (3.4) | 0.058 |
| GLU, median (IQR), mmol/L | 5.1 (4.7–6.4) | 5.1 (4.7–6.8) | 5.5 (4.9–6.0) | 0.984 |
| HB median (IQR), g/L | 137.0 (128.0–149.8) | 138.0 (128.0–150.0) | 137.0 (131.0–146.0) | 0.503 |
| CRP, median (IQR), mg/L | 1.4 (0.5–2.8) | 1.3 (0.5–2.6) | 1.7 (1.0–3.5) | 0.002* |
| UA mean (SD), µmol/L | 307.1 (104.8) | 313.3 (100.3) | 286.9 (116.7) | 0.006* |
| TC, mean (SD), µmol/L | 4.2 (1.2) | 4.2 (1.1) | 4.3 (1.3) | 0.469 |
| T3, median (IQR), pmol/L | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) | 1.2 (1.0–1.3) | 0.043* |
| T4, median (IQR), pmol/L | 110.4 (94.4–127.4) | 110.8 (94.7–126.6) | 103.8 (110.0–130.5) | 0.855 |
| FT3, median (IQR), pmol/L | 4.5 (4.2–4.7) | 4.5 (4.2–4.8) | 4.3 (4.1–4.6) | 0.055 |
| FT4, median (IQR), pmol/L | 11.2 (9.9–12.6) | 11.3 (10.0–12.5) | 10.3 (9.6–13.3) | 0.655 |
| TSH, median (IQR), mIU/L | 2.0 (1.2–3.1) | 2.0 (1.2–3.1) | 2.3 (1.4–3.2) | 0.027* |
| TMAb, median (IQR), IU/mL | 5.0 (2.4–9.8) | 4.5 (2.4–10.6) | 6.9 (1.0–3.5) | 0.195 |
| TGAb, median (IQR), IU/mL | 8.7 (5.2–15.3) | 8.6 (5.2–11.8) | 9.1 (3.9–15.7) | 0.173 |
| HAMD score, median (IQR) | 4.0 (2.0–6.0) | 3.0 (1.0–5.0) | 14.0 (10.0–20.0) | 0.000* |
| Lubben score, median (IQR) | 29.0 (18.0–37.0) | 28.0 (17.0–37.0) | 32.0 (26.0–40.0) | 0.002* |
| Lis, n (%) | 236 (63.4) | 171 (60.0) | 64 (73.6) | 0.254* |
| CMBs, n (%) | 143 (38.4) | 113 (39.8) | 30 (34.5) | 0.386 |
| Perventricular WMH, median (IQR), score | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.029 |
| Deep WMH, median (IQR), score | 1.0 (0–2.0) | 1.0 (0–2.0) | 1.0 (0–2.0) | 0.109 |
| Centrum semiovale EPVS, median (IQR), score | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) | 4.0 (2.0–4.0) | 0.070 |
| Basal ganglia EPVS, median (IQR), score | 3.0 (2.0–4.0) | 3.0 (1.0–4.0) | 3.0 (2.0–4.0) | 0.017* |
| Total burden of cSVD, median (IQR), score | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.031* |

PSD, post-stroke depression; SD, standard deviation; IQR, interquartile range; DM, diabetes mellitus; NIHSS, national institutes of health stroke scale; BMI, body mass index; GLU, serum glucose; HB, hemoglobin; CRP, C-reactive protein; UA, uric acid; TC, total cholesterol; T3, triiodothyronine; T4, thyroxine; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; TMAb, thyroid microsomal antibody; TGAb, thyroid globulin antibody; HAMD, hamilton depression scale; Lis, lacunar infarcts; CMBs, cerebral microbleeds; WMH, white matter hyperintensity; EPVS, enlarged perivascular spaces; cSVD, cerebral small vessel disease.

The p-value for the differences between patients without PSD and PSD.

*Means p < 0.05.

Associations Between Thyroid Hormones and PSD

Table 2 reveals the association between each thyroid hormone and PSD. Univariate analysis suggested that serum T3 and TSH levels were associated with an increased risk of PSD. However, multivariate regression results after adjusting for age and sex indicated that only serum TSH level was positively related to PSD, with an adjusted OR of 1.168 (95% CI, 1.016–1.341; P = 0.029). After adjusting for all the potential confounders in model 2, TSH remained an independent predictor of PSD with an adjusted OR of 1.228 (95% CI, 1.053–1.431; P = 0.009).

Associations Between cSVD and PSD

We also conducted a multivariate logistic regression analysis to assess the association between cSVD and PSD. Among these imaging markers of cSVD, Lis, CMB, and basal ganglia EPVS were significantly associated with PSD (Table 3). After adjusting for age and sex (Model 1), the total burden of cSVD was a risk factor for PSD (OR = 2.079, 95% CI, 1.619–2.671; P < 0.001). Furthermore, after adjusting for more confounders, the association between the total burden of cSVD and PSD remained statistically significant (OR = 2.137, 95% CI, 1.634–2.793; P < 0.001).

Mediation Analysis of Total cSVD Burden on the Association Between TSH and PSD

A significant partial mediation effect for total cSVD burden on PSD was observed. The indirect effect was 0.125 (0.011–0.275), direct effect was 0.35 (0.048–0.629), and total effect was 0.475 (0.095–0.856) (Table 4). Thus, the percentage of the total effect on the TSH-PSD association mediated by the total cSVD burden was estimated at 26.37% (Figure 2).
TABLE 2 | Multivariate logistic regression analysis between each thyroid hormone and PSD.

| Parameter | Model 1 | | Model 2 | |
|-----------|---------|----------------|---------|----------------|
|           | OR      | 95% CI | p        | OR      | 95% CI | p        |
| TSH       | 1.168   | 1.016  | 1.341    | 0.029*  | 1.228   | 1.053  | 1.431    | 0.009*  |
| T3        | 0.422   | 0.157  | 1.136    | 0.088   | 0.708   | 0.245  | 2.043    | 0.523   |
| T4        | 0.998   | 0.987  | 1.010    | 0.739   | 0.998   | 0.986  | 1.010    | 0.733   |
| T3Ab      | 0.996   | 0.976  | 1.016    | 0.693   | 0.995   | 0.973  | 1.017    | 0.652   |
| T4Ab      | 1.006   | 0.995  | 1.017    | 0.308   | 1.006   | 0.995  | 1.018    | 0.275   |

Model 1: adjusted for Age and Sex.
Model 2: model 1 + diabetes mellitus, NIHSS, BMI, CRP, UA, LUBBEN.
T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; T3Ab, thyroid microsomal antibody; T4Ab, thyroid globulin antibody; CI, confidence interval; OR, odds ratio.
*Means p < 0.05.

TABLE 3 | Multivariate logistic regression analysis between the cSVD and PSD.

| Parameter | Model 1 | | Model 2 | |
|-----------|---------|----------------|---------|----------------|
|           | OR      | 95% CI | p        | OR      | 95% CI | p        |
| LIs       | 2.664   | 1.466  | 4.841    | 0.001*  | 2.254   | 1.200  | 4.235    | 0.012*  |
| CMBs      | 1.815   | 1.108  | 2.975    | 0.018*  | 1.981   | 1.169  | 3.537    | 0.011*  |
| Perventricular WMH | 1.149   | 0.882  | 1.498    | 0.304   | 1.139   | 0.856  | 1.515    | 0.373   |
| Deep WMH  | 1.116   | 0.862  | 1.444    | 0.404   | 1.043   | 0.794  | 1.370    | 0.765   |
| Centrum semiovale EPVS | 1.001   | 0.808  | 1.240    | 0.994   | 1.043   | 0.831  | 1.310    | 0.714   |
| Basal ganglia EPVS | 1.311   | 1.038  | 1.655    | 0.023*  | 1.392   | 1.088  | 1.781    | 0.008*  |
| Total burden of cSVD | 2.079   | 1.619  | 2.671    | 0.000*  | 2.137   | 1.634  | 2.793    | 0.000*  |

Model 1: adjusted for Age and Sex.
Model 2: model 1 + diabetes mellitus, NIHSS, BMI, CRP, UA, LUBBEN.
Lis, lacunar infarcts; CMBs, cerebral microbleeds; WMH, white matter hyperintensity; EPVS, enlarged perivascular spaces; cSVD, cerebral small vessel disease; CI, confidence interval; OR, odds ratio.
*Means p < 0.05.

TABLE 4 | Mediation analysis of the effect of the total cSVD burden on the PSD.

| Mediation effect (%) |
|----------------------|
| Unadjusted | 0.099 (0.004–0.212) |
| Model 1     | 0.094 (−0.013–0.235) |
| Model 2     | 0.125 (0.011–0.275) |

Model 1: adjusted for Age and Sex.
Model 2: model 1 + diabetes mellitus, NIHSS, BMI, CRP, UA, LUBBEN.

DISCUSSION

In the present study, we aimed to investigate the association between thyroid hormone levels and PSD at the acute phase of acute lacunar stroke. Our findings suggested that only serum TSH was an independent predictor of PSD. Additionally, mediation analyses indicated that cSVD was a mediating factor in the association between TSH levels and PSD.

Although the association between TSH and depression has been extensively investigated, studies have been conducted in population groups with different diseases. A Danish population-based study indicated that suppressed TSH seems to be associated with the risk of subclinical depression (35). However, a study in patients with autoimmune disease showed that TSH levels were not different in patients with or without depression (36). In contrast, a considerable amount of available evidence elucidated that the prevalence of depressive symptoms in patients with hypothyroidism or subclinical hypothyroidism (SCH) is higher (37). A study including 216 patients with Graves’ disease revealed that patients with SCH might have an increased risk of depression.
(38). Consistent with previous research, our results showed the same trend in patients who had acute ischemic lacunar stroke.

Research into PSD has blossomed over the past 2 decades. Previous studies (19, 21) established that cSVD was associated with both thyroid function and PSD, which was similar to the results of our research. However, we further analyzed the relationship among cSVD, thyroid function, and PSD and believed that there was a mediating effect among them. In addition, the extent to which it is mediated by cSVD has been poorly investigated. Our results showed that 26.37% of the association between TSH and PSD was mediated by cSVD. Our study might have two contributions to the field. First, our findings suggested that serum TSH levels on admission might predict depression after acute ischemic lacunar stroke. The risk factors associated with PSD would help to identify the disease and intervene in advance. On the other hand, it is an attempt to further explore the underlying mechanism of PSD. To the best of our knowledge, this is the first study to explore the role of cSVD in the association between TSH levels and PSD.

Previously, investigators proposed the “brain hypothyroidism” hypothesis to explain the association between TSH and PSD (39). The theory believes that depression is a state of local hypothyroidism in the brain that can be attributed to brain type II deiodinase inhibition as well as impaired transport of T4 across the blood-brain barrier (BBB). However, the theory cannot explain the role of cSVD in the association between TSH and PSD. Researchers later found that deficiency of thyroid hormone can also impair blood vessel function (40). Subclinical hypothyroidism can impair the relaxation of vascular smooth muscle cells, leading to increased systemic vascular resistance and arterial stiffness. This explained the role of cSVD in the association between TSH and PSD. It also provides evidence to support the use of cSVD as a mediating factor to study the relationship between thyroid function and PSD. This is another step forward for understanding the potential mechanism of PSD.

Previous studies (16, 41) usually divide patients into different subgroups, such as the subclinical hypothyroidism group, subclinical hyperthyroidism group, and euthyroidism group, according to reference ranges of serum TSH concentrations and other thyroid hormone concentrations. However, the reference limits of serum TSH concentrations remain controversial (42). For instance, an American study reported the normal reference ranges of serum TSH levels as 0.45–4.5 mIU/L based on the statistically defined reference range (43), whereas another German study based on ultrasound examination defined a normal TSH range of 0.3–0.7 mIU/L (44). Obviously, the range of normal TSH varies from laboratory to laboratory. This in part can be attributed to age, sex, acute illnesses, diurnal variations, and ethnicity (42). In this work, we did not use these reference limits of thyroid hormones but directly used quantitative data for analysis to avoid the abovementioned problems.

In our research, confounding factors were controlled as much as possible. The well-known confounders include age, sex, NIHSS, LUBBEN, diabetes mellitus, CRP, and UA (45, 46). In addition, we also included BMI as a potential confounder because serum TSH levels are elevated in overweight and obese individuals, which may erroneously indicate subclinical hypothyroidism (47). However, we did not take all the possible confounders into consideration, especially iodine intake. Research has found that high iodine intake is a risk factor for overt hypothyroidism. Subclinical hypothyroidism is more common in areas with relatively iodine-rich: 6.1–18.0%, while iodine-deficient areas are 0.9–3.8% (48). Differences in iodine intake will affect research results. Consequently, iodine intake should be considered a potential confounder in further studies.

**Limitations and Recommendations**

There are certain limitations that should be discussed. First, only the acute phase study was conducted in our study, and follow-up data for the subacute and chronic phases were lacking. Hence, future research should investigate the association of TSH and PSD during subacute and chronic phases. Second, the sample size in our study was relatively small. Only 372 patients who had lacunar stroke were recruited for analysis. Thus, large cohort studies should be performed in the future. Third, patients presenting serious cognitive and communication barriers in the study were excluded, so the sample cannot fully represent all patients who had lacunar stroke. It is a fact that we cannot
exclude that lower TSH levels were already present before stroke onset. According to previously published data, the incidence of subclinical hyperthyroidism is no more than 0.5% (49). Despite that, we could still not preclude potential selection bias. This is also a limitation of the article.

In brief, this was an attempt to evaluate the association of thyroid hormones and PSD among patients with lacunar stroke. Future research should consider the following aspects: (1) to confirm the exact association between thyroid hormone levels and PSD in all patients who had stroke; (2) PSD also needs further investigation to determine its association with thyroid axis hormones and other components of the limbic system; and (3) in addition to cSVD, whether there are other factors that also play a mediating role.

CONCLUSION

In conclusion, the investigation demonstrated that serum TSH levels on admission can probably predict depression after acute ischemic lacunar stroke. In addition, our findings highlighted that cSVD played a mediating role in the association of TSH and PSD. Thus, combined TSH and cSVD may be a reasonable and useful approach for the assessment and prevention of PSD in the future.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
18. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* (2010) 9:689–701. doi: 10.1016/S1474-4422(10)70104-6

19. Zhang X, Tang Y, Xie Y, Ding C, Xiao J, Jiang X, et al. Total magnetic resonance imaging burden of cerebral small-vessel disease is associated with post-stroke depression in patients with acute lacunar stroke. *Eur J Neurol.* (2017) 24:374–80. doi: 10.1111/ejn.13213

20. Pavlovic AM, Pekmezovic T, Trajkovic JZ, Medjedovic TS, Veselinovic N, Radiocic A, et al. Baseline characteristic of patients presenting with lacunar stroke and cerebral small vessel disease may predict future development of depression. *Int J Geriatr Psychiatry.* (2016) 31:58–65. doi: 10.1002/gps.4289

21. Zhang XH, Xie Y, Ding CX, Xiao J, Tang YY, Jiang XM, et al. Subclinical hypothyroidism and risk of cerebral small vessel disease: a hospital-based observational study. *Clin Endocrinol.* (2017) 87:581–6. doi: 10.1111/cen.13383

22. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction. The Oxfordshire community stroke project. *Stroke.* (1987) 18:545–51. doi: 10.1161/01.STR.18.3.545

23. Wang JJ, Li FL, Xiao LL, Peng F, Sun W, Li M, et al. Depressed TSH level as a predictor of poststroke fatigue in patients with acute ischemic stroke. *Neurology.* (2018) 91:E1971–E8. doi: 10.1212/WN1.0000000000006534

24. Hamilton M. Rating depressive patients. *J Clin Psychiatry.* (1980) 41:21–4.

25. Mitsunaga W, Higashi T, Morichi T, Koyanagi M, Honda Y, Okita M, et al. Factors related to post-stroke depression during the first 2 weeks after stroke. *Br J Occup Ther.* (2021) 84:15–21. doi: 10.1177/0308022620936865

26. Khedr EM, Abdelrahman AA, Desoky T, Zaki AF, Gamea A. Post-stroke depression: frequency, risk factors, and impact on quality of life among 103 stroke patients-hospital-based study. *Egyptian J Neurol Psychiatry Neurosurg.* (2020) 56. doi: 10.1161/ejnp1983.020-00199-8

27. Berkanovic E, Lubben JE, Kitano HH, Chi I. The physical, mental, and social health status of older Chinese: a cross-national study. *J Aging Soc Policy.* (1994) 6:73–87. doi: 10.1300/J031v06n03_06

28. Chou KH, Lee PL, Peng LN, Lee WJ, Wang PN, Chen LK, et al. Classification differentiates clinical and neuroanatomical features of cerebral small vessel disease. *Brain Commun.* (2021) 3:fcab107. doi: 10.1093/braincomms/fcab107

29. Potter GM, Doubl LF, Jackson CA, Chappell FM, Sedlow CL, Dennis MS, et al. Enlarged perivascular spaces and cerebral small vessel disease. *Int J Stroke.* (2015) 10:376–81. doi: 10.1111/ijs.12054

30. Staals I, Makin SDJ, Doubl FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology.* (2014) 83:1228–34. doi: 10.1212/WNL.0000000000008387

31. Doubl FN, MacLullich AMJ, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. *Stroke.* (2010) 41:450–4. doi: 10.1161/STROKEAHA.109.564914

32. Greenberg SM, Vernooij MW, Cordonnier C, Viswanath An, Salmon RAS, Warach S, et al. Cerebral microbleeds: a guide to detection and interpretation. *Lancet Neurol.* (2009) 8:165–74. doi: 10.1016/S1474-4422(09)7013-4

33. Fazekas F, Klei N, Offenbacher H, Schmidt R, Payler F, et al. Pathological correlates of incidental mri white-matter signal hyperintensities. *Neurology.* (1993) 43:1683–9. doi: 10.1212/wnl.43.9.1683

34. Wardlaw JM, Smith EE, Biesels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* (2013) 12:822–38. doi: 10.1016/S1474-4422(13)70124-8

35. Kvetny J, Ellervik C, Bech P. Is suppressed thyroid-stimulating hormone (TSH) associated with subclinical depression in the Danish General Suburban Population Study? *Nord J Psychiat.* (2015) 69:282–6. doi: 10.3109/08039488.2014.972454

36. Wu XR, Zhang KK, Xing YL, Zhou W, Shao YQ, Li GZ, et al. Dysregulated thyroid hormones correlate with anxiety and depression risk in patients with autoimmune disease. *J Clin Lab Anal.* (2021) 35:e23573. doi: 10.1002/jcla.23573

37. Talaei A, Rafee N, Rafei F, Chehrehi A. TSH cut off point based on depression in hypothyroid patients. *BMC Psychiatry.* (2017) 17:5. doi: 10.1186/s12888-017-1478-9

38. Yu J, Tian AJ, Yuan X, Cheng XX. Subclinical hypothyroidism after 1-131-treatment of graves’ disease: a risk factor for depression? *PLoS ONE.* (2016) 11:e0154846. doi: 10.1371/journal.pone.0154846

39. Foltyn W, Nowakowska-Zajdel E, Danikiewicz A, Brodzia B. Hypothalamic-pituitary-thyroid axis in depression. *Psychiatr Pol.* (2002) 36:281–92.

40. Owen PJD, Sabir R, Lazarus H. Thyroid disease and vascular function. *Thyroid.* (2007) 17:519–24. doi: 10.1089/thy.2007.0051

41. Lee SH, Hong YJ, Kim Y, Park SY, Kim C, Kim YJ, et al. Subclinical hyperthyroidism could predict poor outcomes in patients with acute ischemic stroke treated with reperfusion therapy. *Front Neurol.* (2019) 10:e00782. doi: 10.3389/fneur.2019.00782

42. Cooper DS, Biondi B. Subclinical thyroid disease. *Lancet.* (2012) 379:1142–54. doi: 10.1016/S0140-6736(11)60276-6

43. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease - scientific review and guidelines for diagnosis and management. *JAMA.* (2004) 291:228–38. doi: 10.1001/jama.291.2.2228

44. Volzke H, Alte D, Kohlmann T, Ludemann J, Nauck M, John U, et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. *Thyroid.* (2005) 15:279–85. doi: 10.1089/thy.2005.15.279

45. Li G, Miao J, Si TN, Sun WH, Song XY, Lan Y, Zhao X, et al. Lower serum uric acid is associated with post-stroke depression at discharge. *Front Psychiatry.* (2020) 11:e00052. doi: 10.3389/fpsyt.2020.00052

46. Gao J, Xu W, Han K, Zhu L, Gao Li, Shang XL. Changes of serum uric acid and total bilirubin in elderly patients with major postischemic stroke depression. *Neuropsychiatr Dis Treat.* (2018) 14:83–93. doi: 10.2147/NDT.S149712

47. Biondi B. Thyroid and obesity: an intriguing relationship. *J Clin Endocrinol Metab.* (2010) 95:3614–7. doi: 10.1210/jc.2010-1245

48. Teng WP, Shan XZ, Xing XG, Gao XH, Li YH, Teng D, et al. Effect of iodine intake on thyroid diseases in China. *N Engl J Med.* (2006) 354:2783–93. doi: 10.1056/NEJMoa054022

49. Meng ZW, Liu M, Zhang Q, Liu L, Song K, Tan J, et al. Gender and age impacts on the association between thyroid function and metabolic syndrome in Chinese. *Medicine.* (2015) 94:2193. doi: 10.1097/MD.0000000000002193

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.